Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Joinstar has commercialized multiple in vitro diagnostic products for early detection and management of sepsis and infectious diseases. Their HBP assay for severe sepsis prediction has been launched in partnership with Axis-Shield Diagnostics Limited. The company also developed COVID‑19 antigen rapid tests that are CE marked and distributed globally. They have over 45 NMPA medical device registrations and 29 CE certificates with more than 40 additional products under research or registration.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Joinstar Biomedical Technology.